Title: The Development and Validation of A1c+, a novel multivariable prediction model for the diagnosis of diabetes

Authors: Alan L. Hutchison, MD, PhD*[1], Simar Narula[1] Mary E. Rinella, MD[1], Brandon Faubert, PhD[2], Raghavendra G. Mirmira, MD, PhD[3], William F. Parker, MD, PhD[4]
*Alan.Hutchison@uchicagomedicine.org
1. Section of Gastroenterology, Hepatology and Nutrition,
2. Section of Hematology and Oncology,
3. Section of Endocrinology, Diabetes and Metabolism,
4. Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago Medicine, Chicago, IL, 60637

Key Points

Question Are individuals with diabetes only diagnosable by oral glucose tolerance test (OGTT) at similar risk of mortality as those diagnosed by hemoglobin A1c or fasting plasma glucose (FPG)? Can readily-available clinical data improve diagnosis?

Findings Stratifying NHANES subjects by OGTT-only (1.34%) vs A1c or FPG diagnosis (4.13%) of diabetes found that OGTT-only diagnosis had equivalent mortality. A model combining A1c and standard clinical features (A1c+) had superior AUROC for diabetes compared to the A1c alone. The addition of FPG (A1c/FPG+) had superior AUROC compared to the FPG and A1c+. The A1c/FPG+ predictions strongly associated with mortality in subjects with sub-diagnostic A1c and FPG.

Meaning Incorporation of clinical features can improve diabetes diagnosis missed by A1c and FPG. Model prediction of diabetes associates with mortality.

Abstract

Importance: The hemoglobin A1c and fasting plasma glucose (FPG) have known limitations for diabetes diagnosis, but models to identify individuals who would benefit from 2-hour oral glucose tolerance testing (OGTT) are limited.

Objective: To determine if OGTT-only diagnosed diabetes has comparable outcomes to A1c- or FPG-diagnosed diabetes and if standard clinical features could be leveraged to identify undiagnosed diabetes.

Design: Multivariable prediction model development and validation.

Setting: US National Health and Nutrition Examination Survey (NHANES) data with corresponding US National Center for Health Statistics (NCHS) mortality data.

Participants: Of 105,862 NHANES subjects from 1999 to 2016, we identified 13,800 subjects with FPG, A1c, or OGTT results (11,550 with mortality data) and 92,062 other subjects (53,255 with mortality data).

Exposure: OGTT-diagnosed diabetes

Main Outcomes and Measures The primary outcomes were association of mortality with diabetes diagnostic approach and models to diagnose diabetes. We used a gradient boosted machine decision tree to predict diabetes from standard clinical features. In the test set, we compared the AUROC and the net benefit by decision curve analysis to A1c, FPG, and a combination of the two. We performed survival analysis based on method of diabetes diagnosis and diabetes model predictions.

Results The rate of OGTT-only diabetes was 1.34%. Subjects with OGTT-only diabetes had equivalent risk of mortality compared to subjects with FPG- or A1c-diagnosed diabetes after adjusting for age, sex, and race/ethnicity. A model using the A1c and standard clinical features (A1c+ model) outperformed the A1c to exclude diabetes (Sensitivity at Youden's Index: 0.72 vs. 0.37). Adding FPG to that model (A1c/FPG+) outperformed FPG for excluding diabetes (Sensitivity: 0.87 vs. 0.48). Subjects with A1c/FPG+-predicted diabetes but sub-diagnostic A1c and FPG had equivalent mortality (HR=8.2, $p<2*10^{-16}$) to those with A1c or FPG-diagnosed diabetes (comparison $p<0.17$).

Conclusions and Relevance Diabetes diagnosed by OGTT alone has equivalent mortality to A1c and FPG-diagnosed diabetes. A model using standard clinical features can bolster the A1c and FPG to identify potentially undiagnosed diabetes. Model predictions associated with mortality equivalently to having a diabetes diagnosis. Implementation of a clinical decision support tool could improve diagnosis of diabetes and lead to earlier interventions.

Introduction:

The diabetes epidemic continues to grow in the United States, impacts an estimated 38.4 million people (8.7 million likely undiagnosed), and generates health care costs of $412.9 billion per year[2,3]. The American Diabetes Association (ADA) recommends the hemoglobin A1c (A1c), fasting plasma glucose (FPG), or oral glucose tolerance test (OGTT) for the diagnosis of diabetes. The A1c has become the predominant method clinically due to its ease of use[4,5]. However, A1c is inaccurate in the setting of chronic diseases such as chronic kidney disease, heart failure, cirrhosis, and after solid organ transplant[6,7], which are all increasing in prevalence[2,8-10]. FPG is more sensitive in some populations in which the A1c is inaccurate, but requires fasting. OGTTs are recommended in these patient populations[11], but application at the population-level is hindered by high rates of non-adherence[12,13]. It is unclear how concerning this is for the general population: the current number of US residents in whom diabetes is only diagnoseable by OGTT (OGTT- only) is unknown, as is the current relevance of OGTT- only diabetes. Here, we investigate the rate of OGTT-only diabetes and its association with mortality.

If OGTT-only diabetes is significant – identifying patients with A1c < 6.5% and FPG < 126 mg/dL who need OGTT would be challenging, and would need to be performed by already-taxed[14] general practitioners. Clinical decision support tools could aid in this detection[15,16]. This used to be a laborious process, but with the widespread adoption of the electronic medical record significant amounts of patient data are readily accessible within these systems, allowing for machine learning solutions to this diagnostic dilemma. A powerful machine learning approach, decision tree analysis, overcomes the problems of collinearity and missing data that impact large dataset analysis. The premiere decision tree algorithm is a gradient-boosted decision tree analysis, XG Boost[17], which has been used to predict outcomes such as sepsis, heart failure mortality, and decompensated cirrhosis[18-20]. Prior machine learning approaches have improved detection of diabetes, but these have focused on patient-reported history [21,22] as their predictive label, as opposed to the clinical difficult-to-obtain 2 hour glucose from an OGTT. Liu *et al.* use the 2-hour glucose in a Chinese population, but focus on patient history questions more than standard lab values, and do not focus on chronic diseases [23]. Here, we develop an XG Boost-based machine learning model to predict diabetes using A1c, features normally obtained during standard care, and with and without FPG, which would guide ordering of an OGTT.

In this work, we aim to understand the association of diabetes diagnosed by OGTT alone with mortality, to develop and validate machine learning multivariate prediction models to identify diabetes missed by A1c and FPG but diagnosed by OGTT, and to assess the association of predicted diabetes with mortality.

Methods:

This study used data from the National Health And Nutrition Examination Survey (NHANES), a national survey of U.S. residents. A subset of subjects in NHANES from 1999-2016 received A1c and FPG measurements and a subset from 2005-2016 received A1c, FPG, and OGTT measurements. Of these, many have corresponding mortality data available from the National Center for Health Statistics. Data were divided into the training (NHANES years 2005-2014) and evaluation (NHANES years 2015-2016) datasets, in accordance with the TRIPOD-AI guidelines[24].

Primary outcome: Diagnosis of diabetes

The primary outcome was the diagnosis of diabetes based on A1c greater than or equal to 6.5%, FPG greater than or equal to 126 mg/dL, and/or two-hour glucose greater than or equal to 200 mg/dL. For national estimates we resampled the NHANES data using fasting or OGTT-specific weights.

Secondary outcome: Survival

The secondary outcome was survival based on linked mortality data from the NCHS.

Predictor variable extraction:
We extracted a set of standard clinical features, including vital signs, anthropometrics, baseline, fasting, and additional labs (Supplementary Methods, Supplementary Table 1) from NHANES.

To increase the predictive ability of our model, we excluded factors that were missing in more than 12% of the data and removed overlapping variables (Supplementary Table 2). We focused on features that would be already collected during routine standard of care for U.S. adults. In the standard of care model, we included vital signs, patient history, complete blood count and differential, comprehensive metabolic panel, and hemoglobin A1c. A complete blood count and comprehensive metabolic panel are required for screening for metabolic-dysfunction associated steatotic liver disease (MASLD, previously NAFLD), which should be done for patients at risk of pre-diabetes or diabetes[1,25]. We used OGTT-specific NHANES sample weights in our model training.

Model Development: We used gradient-boosted decision tree analysis (XG Boost) to develop two versions of our model. A1c+ included the A1c and all non-fasting lab results and other features described above. A1c/FPG+ additionally included the fasting plasma glucose. See the Supplemental Methods for further information.

Model evaluation: For model comparison, the model test characteristic diagnostic thresholds were determined using Youden's index. In the evaluation dataset, we compared 1) A1c+ non fasting to standard approach of A1c ≤ 6.5% and 2) A1c+ fasting to the standard approach of A1c ≤ 6.5% or FPG ≤ 126 mg/dL. We compared models based on input characteristics, area-under-the-receiver-operating-curve, sensitivity, specificity, and net benefit.

Survival analysis: We generated Kaplan-Meier curves to estimate and visualize survival probabilities according to mode of diagnosis. We tested differences in survival based on diagnosis and prediction of diabetes using survey-weighted Cox proportional hazard regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. We performed unadjusted and age, sex, and race/ethnicity-adjusted analysis comparing mode of diabetes diagnosis. As model-based diabetes predictions incorporated age, sex, and race/ethnicity, we did only unadjusted analysis for the model-based survival analyses. To account for the weighted sample, we used masked variance pseudo-strata (PSU) and masked variable pseudo-PSU in addition to MEC sample weights, fasting sample weights, and OGTT sample rates where appropriate. See the Supplemental Methods for further information.

Sensitivity analyses: One potential limitation of the A1c and FPG thresholds is that they may not be calibrated to a modern 2005-2016 population. To account for this and to further validate the strength of our models, we performed sensitivity analyses where we allowed the A1c and FPG to vary, thereby generating an AUROC for the A1c and FPG. Likewise, we generated an XGBoost model using the A1c and FPG (A1c+FPG) alone for comparison.

Results:

Patient characteristics
From 1999 to 2016, 105,862 subjects had laboratory measurements, but only 13,800 of the 60,936 subjects from 2005-2016 received OGTT testing (STROBE Diagram, Supplementary Figure 1). Of those 13,8000 subjects, the mean age of the cohort was 40 years (± 20.5) and 49.8% were female. 42% subjects were non-Hispanic white, 20% Black, 18% Mexican-American, 10% other Hispanic, and 10% other / multi-racial. The average height was 167 cm (± 10), the average weight was 78 kg (± 22), the average waist circumference was 95 cm (± 17), and the average systolic and diastolic blood

pressures were 120 mmHg (± 17) and 67 mmHg (± 13), respectively. The average FPG was 100.2 mg/dL (± 17.9), the average A1c was 5.4% (±0.6), and the average two-hour glucose was 117 mg/dL (± 49). Table 1 shows the summary top twenty features in the FPG/A1c+ model (discussed below) for the 2005-2014 and 2015-2016 cohorts, as well as for the subjects from 1999-2016 who did not have OGTT testing.

National prevalence of diabetes by diagnosis type:

Resampling the 13,800 subjects based on NHANES-assigned sampling weights, the prevalence of diabetes diagnosed by any method was 5.46%, while 1.34% of the population had diabetes diagnosed by OGTT alone. Supplementary Table 3 shows the confusion matrix for the diagnosis of diabetes and pre-diabetes. To better understand this discordance, we compared the A1c to the two-hour glucose in individuals with an A1c less than 6.5% in the setting of different comorbidities: chronic kidney disease, anemia, obesity, liver fibrosis, age, and hypertension. The relationship between the A1c and the two-hour glucose varied widely across these (Supplementary Figure 2).

Association of diabetes diagnosis with mortality

In the 2005-2016 cohort, 11,500/13,8000 subjects had paired NCHS mortality data. We separated subjects by no diagnosis of diabetes, diagnosis of diabetes by at least A1c or FPG, and diagnosis of diabetes by OGTT alone. We found that subjects with OGTT-only diabetes had a 5 times increased risk of mortality compared to those without diabetes ($p<2x10^{-16}$) and a 1.3 times increased risk of mortality compared to those with diabetes diagnosed by A1c or FPG (independent of if their OGTT was also diagnostic) ($p<0.03$). When we adjusted for age, sex, and race/ethnicity these effect sizes decreased (OGTT-only vs no diabetes: HR=1.6, $p<0.0004$; OGTT-only vs A1c/FPG diabetes: HR=1.0, $p=0.98$) (Figure 1A). OGTT-only diabetes had equivalent odds of resulting in diabetes being a leading cause of death (Figure 1B), but lower rates of resulting in diabetes being a contributing cause of death (Figure 1C). This finding of a substantial survival difference for OGTT-only diabetes, even if accounted for by age, sex, and race/ethnicity, as well as equivalent rates of diabetes being the leading cause of death, motivated us to develop a model to detect diabetes missed by A1c or FPG that would include such demographic data.

Top features of interest in diabetes prediction

We first examined the 20 most important features from all the included variables, shown as a Shapley plots in Supplementary Figure 4. We found that the laboratory values that are affected by fasting (fasting plasma glucose, insulin, triglycerides, and iron) had a large predictive effect, ranking #1, #5, #8, and #16, respectively. Clinically-accessible vital signs included age, height, systolic blood pressure, waist circumference, diastolic blood pressure, and weight. The most important non-fasting labs were the A1c, urine albumin, percentage of segmented neutrophils, gamma-glutamyl transferase (GGT), creatinine, percentage of lymphocytes, lactate dehydrogenase (LDH), cholesterol, and alanine aminotransferase (ALT). The Poverty Ratio of the zip code of the participant was also in the top 20 variables (#19). Focusing on the more clinically applicable A1c+ model (Figure 2), which excluded the fasting labs fasting plasma glucose, insulin, triglycerides, and iron, and excluded the less-commonly obtained urine albumin, GGT, cholesterol, and LDH, we found that the aspartate aminotransferase (AST), hemoglobin, total protein, pulse, arm circumference, platelets, percentage of monocytes, and mean corpuscular volume were among the other features in the top 20 features of importance.

Comparison of clinically accessible variables with A1c and FPG for diagnosing diabetes

We compared our non-fasting routine clinical feature model (A1c+) and A1c/FPG+ model (as described in *Methods)* to the current diagnostic thresholds of the A1c of 6.5% (A1c.Fixed) and FPG of 126 mg/dL (FPG.Fixed), as well as sensitivity analyses against models where the A1c and FPG were allowed to

fluctuate to different thresholds (Figure 3, Supplementary Figure 5). Among the non-fasting approaches (A1c.Fixed, A1c, and A1c+), the A1c+ model outperforms the others, with an AUROC of 0.88 and sensitivity of 0.72 compared to the A1c AUROC of 0.83 and sensitivity of 0.66 and A1c.Fixed sensitivity of 0.37 (Figure 3A). Among the fasting approaches, the A1c/FPG+ model outperformed the simpler approaches, with an AUROC of 0.95 and a sensitivity of 0.87 compared to the FPG AUROC of 0.92 and sensitivity of 0.84, with a FPG.Fixed sensitivity of 0.48 (Figure 3B).

To establish the utility of our models with a complementary method, we employed Decision Curve Analysis (Figure 3B). Decision Curve Analysis measures the net benefit difference between the approaches based on what risk of diabetes would be needed to convince patient or provider to order additional testing (in this case, an oral glucose tolerance test). For a diagnosis of diabetes, the benefit of the A1c+ model over the A1c and the benefit of the A1c/FPG+ model over the FPG extended from 5% to 25%, and across the entire range of risk compared to the A1c.Fixed.

For completeness, we included additional models, including a combined FPG+A1c XG Boost model and a model using all the available features (Full). The FPG+A1c model underperformed the A1c/FPG+ model by AUROC and sensitivity, and the Full model was equivalent to the simpler A1c/FPG+ model, justifying the use of the simpler A1c/FPG+ model (Supplementary Figure 5). We repeated our model building and analysis instead using the thresholds for pre-diabetes and diabetes together (A1c ≥ 5.7%, FPG ≥ 100 mg/dL, and 2hG ≥ 140 mg/dL). In that setting, the A1c+ model outperformed the A1c and the A1c/FPG+ performed equivalently to the FPG+A1c and Full model in outperforming the FPG (Supplementary Figure 6).

Association of A1c/FPG+ model predictions with mortality

To assess the importance of our model predictions, we applied the A1c/FPG+ model to the 92,062 subjects in NHANES from 1999-2016 who did not have OGTT measurements (and therefore were not used for model training or evaluation), of whom 53,255 subjects had mortality data. We stratified the subjects into those with A1c- or FPG-diagnosed diabetes, those with sub-diagnostic A1c and FPG but with A1c/FPG+-predicted diabetes, and those with sub-diagnostic A1c and FPG but without A1c/FPG+-predicted diabetes (Figure 4A). We found that model-predicted diabetes (green line) was statistically indistinguishable from A1c- or FPG-diagnosed diabetes (red line) for their association with mortality when compared to subjects without diabetes or predicted diabetes (blue line), with HR = 8.2, $p < 2*10^{-16}$ compared to HR = 8.2, $p < 2*10^{-16}$, respectively (comparison HR=1.1, p<0.17). We found that prediction of diabetes among those without a diagnosis of diabetes was associated with higher odds of diabetes being a leading or contributing cause of death compared to those without a diagnosis of prediction of diabetes (0.89% vs. 0.25% and 6.63% vs 3.31%, respectively), though this was lower than the odds of diabetes as a leading or contributing cause of death for those with an A1c or FPG-based diagnosis of diabetes (Figure 4B & C).

Discussion

In this study, we demonstrate that 1) OGTT-only diabetes has a higher (and equivalent if controlling for age, sex, and race/ethnicity) association with mortality compared to diabetes diagnosed by A1c or FPG, with equivalent risk of diabetes being the leading cause of death, 2) a machine learning model using features collected during standard medical visits can improve detection of diabetes, and 3) this machine learning-predicted diabetes associates with mortality equivalently to A1c- or FPG-diagnosed diabetes and associates with increased risk of diabetes being the leading or contributing cause of death compared those without predicted diabetes.

We have reaffirmed the importance of OGTT-only diabetes as having equivalent risk of death and diabetes-related death as diabetes diagnosed by A1c or FPG. Studies in earlier populations had established the predictive role of OGTT for mortality[26], but this had not been examined in a modern 21st-century cohort. While the underlying pathophysiology of post-prandial hyperglycemia may differ from the elevated hepatic insulin resistance that drives increases in fasting plasma glucose, the risk of mortality appears to not change. From 2005-2016 over 1 in 100 individuals had OGTT-only diabetes. These individuals are missed by A1c and/or FPG screening approaches conventionally used, justifying the need for a means to identify these individuals that would otherwise be missed despite having equivalently bad outcomes.

We have developed a machine learning model that can easily integrate into clinical care, as it does not require additional vitals, demographics, or lab tests other than what are routine clinical features for a U.S. adult. Given this is information available in the electronic medical record, future integration of A1c/FPG+-type models into the electronic medical record (EMR) should guide screening. Additional models could be developed and validated that would tailor included clinical features to specific patient populations. This will be especially of use to general practitioners, who may not have the same familiarity with conditions that would require more extensive testing for diabetes with OGTT or bandwidth to pursue the work-up and diagnosis. In the setting of a sub-diagnostic A1c, an EMR model that calculated a high risk of diabetes could trigger an alert recommending fasting labs, and if the FPG was sub-diagnostic again an EMR model with a high risk could trigger a recommendation to obtain an OGTT, or at the very least repeat follow-up labs quickly (Supplementary Figure 7). While earlier detection and therefore earlier glucose control should lead to improved outcomes, further work and implementation will be needed to validate this.

The predictions of diabetes from the machine learning models are meaningful – subjects with the predictions with a diagnosis of diabetes have as high risk of mortality as those with diagnosed diabetes. There is strong evidence that the pathophysiological damage done by uncontrolled diabetes in the first few years after diagnosis has lifelong consequences. Diabetes was subsequently discovered in these subjects, as evidenced by diabetes appearing as a leading or contributing cause of death in the NCHS data. Earlier detection, especially now that there are multiple effective and complementary modalities for treating diabetes, could reduce this mortality. This paper and machine learning models offer a framework for providing that earlier detection.

These machine learning models and paper provide the groundwork for further work on this topic. This study externally validates the model using mortality data from NCHS – these machine learning models should be validated using other general population datasets as well as ideally chronic-disease specific datasets. Focusing on chronic diseases where the A1c is known to be inaccurate, such as a pregnancy, cystic fibrosis, pancreatitis, chronic liver disease, and chronic kidney disease, would fine-tune the models where there is a higher pre-test probability of OGTT-only diabetes. This would not necessarily require separate models: the underlying methodological framework of the decision-tree analysis should be able to fine-tune the branches of the tree in which creatinine (#12 in the A1c+ model), lipase, or ALT (#7 in the A1c+ model) is elevated, for example. Further work could also focus on the continuous

aspect of prediction: here, we threshold on predicting diabetes vs. no diabetes, despite losing statistical power doing so[27]. Instead, a continuous risk score may better guide when to repeat standard testing as opposed to obtaining an OGTT, and the timeline in which to pursue these options.

Conclusion

In this work, we have established that diabetes detected by OGTT but missed by A1c and FPG is carries equivalent risk of mortality. We have developed models that incorporate routine clinical features to detect diabetes that outperform the A1c and FPG, even if allowing recalibration of the A1c and FPG thresholds. We show the model-diagnosed diabetes in those without a diagnosis of diabetes have equivalent mortality to those with a diabetes diagnosis. Future work will need to validate, refine, and integrate these findings to improve our ability to personalize diabetes risk-stratification for patients.

Supplementary Methods

For National Health and Nutrition Examination Survey (NHANES) data between 1999 and 2004, we included the surveys *Demographics (DEMO), Blood Pressure (BPQ), Diabetes (DIQ)* and *Medical Conditions (MCQ) Questionnaires.* We additionally included *Body Measurements (BMX), Blood Pressure (BPX), Complete Blood Count (LAB25* for 1999-2000, *L25* for 2001-2004*), Biochemistry Profile (LAB18* for 1999-2000 and *L40* for 2001-2004*), Glycohemoglobin (LAB10* for 1999-2000 and *L10* for 2001-2004*),* and *Plasma Fasting Glucose, Serum C-peptide & Insulin (LAB10AM* for 1999-2000 and *L10AM* for 2001-2004*)* data. For 2001-2002 data, Alkaline Phosphatase measurements were taken from *L40_2_B*. We adjusted lab values to 2015-2016 measurements in accordance with NHANES recommendations based on changes in methodology and laboratory measurement techniques.

For NHANES data between 2005 and 2016, we included the surveys *Demographics (DEMO), Alcohol Use (ALQ), Blood Pressure (BPQ)*, *Diabetes (DIQ),* and *Medical Conditions (MCQ) Questionnaires.* We additionally included *Body Measurements (BMX), Blood Pressure (BPX)*, *Complete Blood Count (CBC), Biochemistry Profile (BIOPRO), Glycohemoglobin (GHB)*, *Magnesium and Related Tests (MGX),* Fasting Questionnaire (*FASTQX), Hepatitis A (HEPA, Hepatitis B (HEPB_S), Hepatitis C (HEPC),* and *Hepatitis E (HEPE)* data. We adjusted lab values to 2015-2016 measurements in accordance with NHANES recommendations based on changes in methodology and laboratory measurement techniques. Other than OGTT measurements, when generating the A1c+ and A1c/FPG+ models, we excluded features that were not present in both 1999-2004 and 2005-2016 cohorts.

XG Boost splits the data into separate branches at decision points (*e.g.* age greater than or less than 60 years), combines variables (*e.g.* left leg length and right leg length), and tunes thousands of parameters to optimize the model. Attempts to calibrate predictions using training (2005-2012), validation (2013-2014), and testing (2015-2016) datasets did not change the Brier scores used to evaluate quality of fit, so this calibration was not pursued, and training (2005-2014) and testing (2015-2016) data splitting was used as above. We used gradient boosted decision trees in *R* using the *xgboost* package and *caret* for hyperparameter tuning. The *AUC* and *pROC* packages were used for confusion matrix calculations, the *glm* package was used for binomial modeling, and the *dcurves* package was used for Decision Curve Analysis modeling. Plotting was done using *cowplot* and *ggplot2.* Kaplan-Meier curves were generated with the *survminer* package and Cox Proportional Hazard modeling was performed with the *survival* package. We employed survival analysis methods to compare mortality between groups in *R* using the *survey* and *survminer* packages. We compared odds of diabetes being a leading or contributing cause of mortality also using the *survey* package. Incorporation of OGTT sample weights (WTSOG2YR), fasting weights (WTSAF2YR), examination weights (WTMEC2YR), and strata weights (SDMVSTRA, SDMVPSU) were employed for resampling and statistical testing. R Markdown files and data are available at the *GitHub* repository

alanlhutchison/NHANES-DMDx, and the raw data is available from the Center for Disease Control and Prevention.

In total, the features included the following: basic information: vital signs collected in clinic, demographics, complete blood count, comprehensive metabolic panel, and A1c; fasting labs: fasting plasma glucose, fasting triglycerides, fasting insulin, and fasting iron; social determinants of health questionnaire; additional labs that may not be as frequently obtained in routine clinical care: the urine labs urine albumin and urine creatinine, the blood labs phosphorus, total cholesterol, gamma-glutamyl transferase (GGT), Hepatitis B core and surface antibody, globulin, lactate dehydrogenase, hydroxycontine, hepatitis A total antibody, and osmolality.

Acknowledgements
We would like to thank Dr. Esra Tasali and Dr. Celeste Thomas for their feedback in preparation of this manuscript. No patients were involved in this study design or preparation of this manuscript. This study was evaluated by the University of Chicago IRB (study ID 25-1210) and deemed to be exempt from further review.

Funding
Dr. Hutchison has received support from NIH T32 DK007074, and the American Association for the Study of Liver Diseases. Dr. Mirmira is supported by NIH U01 DK127786, R01 DK060581, and R01 DK105588. Dr. Parker is supported by NIH R01LM014263 and the Greenwall Foundation. Dr. Hutchison, Dr. Parker, Dr. Mirmira, and Dr. Rinella have no relevant financial disclosures.

Figures and Tables

Table 1: Top 20 features of interest in A1c/FPG+ model to predict diabetes for the non-OGTT 1999-2016 cohort, OGTT 2005-2014 cohort (used as a training cohort), and the OGTT 2015-2016 (used as a validation cohort).

	1999-2016, No OGTT	**2005-2014, OGTT**	**2015-2016, OGTT**
N	**92,062**	**11,718**	**2,082**
Fasting Plasma Glucose			
Mean (SD)	108.1 (±43.1)	101.8 (±18.0)	102.6 (±18.9)
Missing	77,452 (84.1%)	0 (0%)	0 (0%)
Age			
Mean (SD)	29.0 (±25.1)	41.1 (±20.6)	41.8 (±20.3)
Missing	13,842 (15.0%)	0 (0%)	0 (0%)
Hemoglobin A1c			
Mean (SD)	5.6 (±1.1)	5.4 (±0.6)	5.5 (±0.6)
Missing	46,967 (51.0%)	0 (0%)	0 (0%)
Waist Circumference			
Mean (SD)	84.6 (±22.4)	94.4 (±16.7)	95.9 (±17.5)
Missing	28,576 (31.0%)	189 (1.6%)	41 (2.0%)
Systolic Blood Pressure			
Mean (SD)	119.0 (±19.6)	119.2 (±16.8)	121.7 (±17.5)
Missing	39,054 (42.4%)	258 (2.2%)	26 (1.2%)
Height			
Mean (SD)	153.7 (±24.6)	167.4 (±10.1)	166.3 (±10.1)
Missing	25,601 (27.8%)	73 (0.6%)	7 (0.3%)
% Segmented Neutrophils			
Mean (SD)	54.4 (±12.1)	56.1 (±9.9)	55.8 (±9.4)
Missing	30,629 (33.3%)	43 (0.4%)	9 (0.4%)
% Lymphocytes			
Mean (SD)	33.9 (±11.1)	31.9 (±8.8)	32.2 (±8.7)
Missing	30,629 (33.3%)	43 (0.4%)	9 (0.4%)
ALT			
Mean (SD)	24.0 (±24.0)	24.5 (±19.8)	23.6 (±14.0)
Missing	47,828 (52.0%)	99 (0.8%)	6 (0.3%)
Platelets			
Mean (SD)	276.9 (±75.9)	251.4 (±66.4)	237.5 (±58.8)
Missing	30,476 (33.1%)	22 (0.2%)	9 (0.4%)
AST			
Mean (SD)	25.2 (±16.9)	25.7 (±20.0)	24.7 (±10.8)
Missing	47,830 (52.0%)	102 (0.9%)	6 (0.3%)
Creatinine			
Mean (SD)	0.8 (±0.4)	0.8 (±0.3)	0.8 (±0.3)
Missing	47,748 (51.9%)	81 (0.7%)	6 (0.3%)
Diastolic Blood Pressure			
Mean (SD)	66.2 (±13.9)	67.1 (±11.9)	67.2 (±11.6)
Missing	39,264 (42.6%)	309 (2.6%)	32 (1.5%)
Poverty Ratio			
Mean (SD)	2.2 (±1.6)	2.5 (±1.6)	2.4 (±1.6)
Missing	20,797 (22.6%)	817 (7.0%)	193 (9.3%)
Total Protein			
Mean (SD)	7.3 (±0.5)	7.2 (±0.5)	7.2 (±0.4)
Missing	47,797 (51.9%)	89 (0.8%)	6 (0.3%)
Hemoglobin			
Mean (SD)	13.7 (±1.5)	14.3 (±1.5)	14.1 (±1.5)
Missing	30,475 (33.1%)	21 (0.2%)	9 (0.4%)
Arm Circumference			
Mean (SD)	27.5 (±8.0)	32.1 (±5.3)	32.3 (±5.4)
Missing	22,117 (24.0%)	142 (1.2%)	28 (1.3%)
Pulse			
Mean (SD)	75.1 (±12.9)	72.1 (±11.8)	72.3 (±11.4)
Missing	38,525 (41.8%)	220 (1.9%)	25 (1.2%)
% Monocytes			
Mean (SD)	8.0 (±2.4)	8.1 (±2.4)	8.2 (±2.1)
Missing	30,629 (33.3%)	43 (0.4%)	9 (0.4%)
Weight			
Mean (SD)	58.4 (±32.2)	77.8 (±21.5)	78.5 (±22.0)
Missing	19,227 (20.9%)	67 (0.6%)	8 (0.4%)



*Figure 1. The subjects with diabetes diagnosed via OGTT alone had equivalent mortality to those with diabetes diagnosed with A1c and/or FPG (A), though they equivalent rates of diabetes being the leading cause of death (B) and they had lower rates of diabetes as a contributing cause of death, though this was still higher than those without a diagnosis of diabetes altogether (C). Comparison of mortality (A), diabetes as a leading cause of death (B), and diabetes as a contributing cause of death (C) from NCHS data for NHANES 2005-2016 cohorts that had OGTT measurement stratified by subjects with a diagnosis of diabetes by A1c ≥ 6.5% or FPG ≥ 126 mg/dL (red), subjects with a diagnosis of diabetes by OGTT alone (2-hour glucose > 200 mg/dL but A1c < 6.5% and FPG < 126 mg/dL), or subjects without a diagnosis of diabetes. (A) Kaplan-Meier curves of mortality stratified by presence and diagnostic method of diabetes. Comparisons made adjusting for age, sex, and race/ethnicity. For the * and + comparisons the reference is to subjects without diabetes. For the Δ comparison the reference is to the subjects with diabetes diagnosed by OGTT alone. (B and C) Odds of diabetes being a leading (B) or contributing (C) cause of death stratified by diagnosis type. * indicates p < 0.011, ** indicates p < 0.001, and *** indicates p<2x10^{-7}.*



Figure 2. Plot of Shapley values for top 20 features of the A1c+ model. Each point represents a subject, with the Shapley (SHAP) value representing the contribution of a feature value to the difference between the actual prediction and the mean prediction without that feature. Positive values indicate a positive effect on the probability of diabetes, and negative values indicate a negative effect. RBC: Red Blood Cell; Corp: Corpuscular.



Figure 3. (A) Among non-fasting approaches, the routine clinical feature A1c+ model has higher sensitivity than the A1c with and without fixing the diagnostic threshold at 6.5% (A), while among the fasting models the A1c/FPG+ has higher sensitivity than the FPG with and without fixing the diagnostic threshold at 126 mg/dL (C). The A1c+ and A1c/FPG+ models also had superior AUROC (A and C). The Decision Curve Analysis shows that the A1c+ and A1c/FPG+ approaches outperform the A1c and FPG, respectively, from risk thresholds of 5-25%. Points in (A) and (C) indicate True Positive Rate and False Positive Rate of fixed thresholds for A1c=6.5% and FPG=126 mg/dL. Diagonal line in (A) and (C) indicates test characteristics of a random test. Dotted lines in (B) and (D) indicate the net benefit of testing all candidates or testing no candidates with oral glucose tolerance testing for diagnosis of diabetes.



*Figure 4. The subjects without diabetes at time of exam that were predicted to have diabetes via the A1c/FPG+ model had risk of mortality equivalent to those with diabetes (A), and a higher risk having diabetes as the leading cause (B) or contributing cause (C) of death compared to those not predicted to have diabetes by the A1cFPG+ model. Comparison of mortality (A), diabetes as a leading cause of death (B), and diabetes as a contributing cause of death (C) from NCHS data for NHANES 1999-2016 cohorts that did not have OGTT measurement stratified by subjects with a diagnosis of diabetes by A1c ≥ 6.5% or FPG ≥ 126 mg/dL (red) and subjects without a diagnosis of diabetes (A1c < 6.5% and FPG < 126 mg/dL) based on whether the A1c/FPG+ model predicts (green) or does not predict (blue) a diagnosis of diabetes. (A) Kaplan-Meier curves of mortality stratified by presence and prediction of diabetes. For the * and + comparisons the reference is to subjects with A1c < 6.5%, FPG< 126 mg/dL, and no prediction of diabetes. For the Δ comparison the reference is to the subjects with A1c < 6.5%, FPG< 126 mg/dL, and predicted diabetes. Prediction of diabetes in subjects without diabetes at time of exam increased risk of diabetes being the leading (B) or contributing (C) cause of death. * indicates p < 0.008, ** indicates p < 0.0003, and *** indicates p < $4x10^{-10}$.*

Supplementary Figures and Tables

Supplementary Table 1. Features included in the machine learning Full model. Bolded are the top 20 features in the A1c+ model.

Feature Type	Feature
Obtained in Clinic	**Age**, Gender, **Pulse**, **Systolic Blood Pressure**, Diastolic Blood Pressure, **Height**, **Weight**, **Waist Circumference**, Arm Circumference, (Ir)Regularity of Heartbeat
History-obtained	Have you ever been told you had (High BP, Overweight, Pre-diabetes, Poor Sleep, Diabetes, Asthma) Have you ever been treated for Anemia Have you ever received a transfusion? How many hours of sleep do you have a night? Do you have a relative with asthma? Have you been tested for DM in the past 3 years?
CBC & Differential	**Hemoglobin**, White Blood Cell count, **Platelet count, Mean Corpuscular Volume,** Mean Platelet Volume, Red Blood Cell Count, Mean corpuscular hemoglobin concentration, **Percentage of (Neutrophils**, **Lymphocytes**, **Monocytes**, Eosinophils, Basophils), Mean Cell Hemoglobin, RBC Distribution Width
Comprehensive Metabolic Panel + Hemoglobin A1c	Sodium, Potassium, Chloride, Bicarbonate, Blood Urea Nitrogen, **Creatinine**, Calcium, **Total Protein**, Total Bilirubin, Albumin, **Aspartate aminotransferase (AST), Alanine aminotransferase (ALT)**, Alkaline Phosphatase, **Hemoglobin A1c**
Fasting Labs	Fasting Time, Fasting Plasma Glucose, Fasting Triglycerides, Fasting Insulin, Fasting Iron
Social Determinants of Health	**Poverty Ratio**, Race/Ethnicity, Number of People in Household, Marriage Status, Primary Language, Citizenship Status, Education Level
Urine Labs	Urine albumin, Urine creatinine
Various Labs	Total cholesterol, Phosphate, Gamma-Glutamyl Transferase, Hepatitis B surface Antibody, Hepatitis B core Antibody
	Uric Acid, Hydrocontine, Hepatitis A Antibody, Osmolality, Globulin, Lactic Dehydrogenase,

Supplementary Table 2: Redundant features excluded from analysis

Feature	Included Feature	Excluded Features
Blood pressure	Systolic Blood Pressure average	BP site, BP arm, BP cuff peak pressure, BP enhancement usage
Length	Height	Arm length, Upper leg length
Weight	Weight	BMI
Language	Language	Interpreter usage, Proxy usage

Family Size	Number in family	Number in household



Supplementary Figure 1 STROBE diagram.

Supplementary Table 3. Confusion matrix for the ability of the hemoglobin A1c, fasting plasma glucose, and two-hour oral glucose tolerance test thresholds to diagnose diabetes based on resampling 100,000 of the 13,800 subjects in the NHANES 2005-2016 dataset.

A1c ≥ 6.5%		
	FPG ≥ 126 mg/dL	**FPG < 126 mg/dL**
2-hour Glucose ≥ 200	1.07%	0.08%
2-hour Glucose < 200	0.10%	0.14%
A1c < 6.5%		
	FPG ≥ 126 mg/dL	**FPG < 126 mg/dL**
2-hour Glucose ≥ 200	0.80%	1.34%
2-hour Glucose < 200	1.94%	94.54%



Supplementary Figure 2. Relationship between Hemoglobin A1c and two-hour glucose stratified by A1c range. Red lines show thresholds used to diagnose pre-diabetes (140 mg/dL ≤2-hour glucose < 200) and diabetes (2-hour glucose ≥ 200). Data from NHANES 2005-2016 with hemoglobin A1c and two-hour glucose resampled with replacement 100,000 times based on OGTT sample weights. For Hgb comparison Hgb threshold of 13 g/dL was used for subjects classified as male and 11 g/dL for subjects classified as female. eGFR: Estimated Glomerular Filtration Rate (CKD-EPI), Hgb: Hemoglobin, BMI: Body Mass Index (in kg/m^2), FIB4: non-invasive fibrosis risk[1], SBP: Systolic Blood Pressure (in mmHg).



Supplementary Figure 3. Calibration plot of Model-predicted diabetes, grouped by 10 quantiles (x-axis) compared to event rate within that group.



Supplementary Figure 4: Plots of Shapley values for top 20 features of the Full model. Each point represents a subject, with the Shapley (SHAP) value representing the contribution of a feature value to the difference between the actual prediction and the mean prediction without that feature. Positive values indicate a positive effect on the predicted probability of diabetes, and negative values indicate a negative effect. Blue line indicates mean effect for a given value. FPG: Fasting Plasma Glucose; BP: Blood Pressure; GGT: Gamma-Glutamyl-Transferase; %. Neutrophils: Percentage Segmented Neutrophils; Mean Corp. Vol: Mean Corpuscular Volume; LDH: Lactic Dehydrogenase



	Non-Fasting Approaches			Fasting Approaches				
	A1c.Fixed	**A1c**	**A1c+**	**FPG.Fixed**	**FPG**	**FPG+A1c**	**A1c/FPG+**	**Full**
AUROC	NA	0.83	0.88	NA	0.92	0.94	0.95	0.96
Sensitivity	0.37	0.66	0.72	0.48	0.84	0.85	0.87	0.88
Specificity	1	0.88	0.87	1	0.88	0.9	0.92	0.89

Supplementary Figure 5. For diagnosis of diabetes, among non-fasting approaches, the non-fasting routine clinical feature A1c+ model has higher sensitivity than the A1c with and without fixing the diagnostic threshold at 6.5% (A), while among the fasting models the A1c/FPG+ model has higher sensitivity and AUROC than the FPG with and without fixing the diagnostic threshold at 126 mg/dL and the FPG+A1c model, and equivalent sensitivity and AUROC to the Full model. The Decision Curve Analysis (B) shows that the among non-fasting approaches the A1c+ is superior to the A1c, and among the fasting approaches the A1c/FPG+ and Full models are equivalently superior to the FPG and FPG+A1c models. Fasting approaches shown with solid lines, and non-fasting approaches shown with dashed lines. Points indicate True Positive Rate and False Positive Rate of fixed thresholds for A1c and FPG. Diagonal line in (A) indicates test characteristics of a random test. Dotted lines in (B) indicate the net benefit of testing all candidates (black) or testing no candidates (dark green: A1c, light green: FPG) with oral glucose tolerance testing for diagnosis of diabetes.



	Non-Fasting Approaches			Fasting Approaches				
	A1c.Fixed	**A1c**	**A1c+**	**FPG.Fixed**	**FPG**	**FPG+A1c**	**A1c/FPG+**	**Full**
AUROC	NA	0.81	0.87	NA	0.93	0.98	0.99	0.97
Sensitivity	0.37	0.58	0.72	0.48	0.83	0.95	0.95	0.9
Specificity	1	0.91	0.86	1	1	1	1	1

Supplementary Figure 6. (A) Among non-fasting approaches, the non-fasting routine clinical feature model A1c+ had higher sensitivity than the A1c with and without fixing the diagnostic threshold at 6.5% (A, Table), while among the fasting models the A1c/FPG+ performed equivalently to the FPG+A1c and Full models and outperformed the FPG and FPG.Fixed models. The Decision Curve Analysis (B) likewise shows that the among non-fasting approaches the A1c+ is superior to the A1c and among the fasting models the A1c/FPG+ is equivalent to the FPG+A1c models and the FPG+A1c and Full models. Points indicate True Positive Rate and False Positive Rate of fixed thresholds for A1c and FPG. Diagonal line in (A) indicates test characteristics of a random test. Dotted lines in (B) indicate the net benefit of testing all candidates (black) or testing no candidates (dark green: A1c, light green: FPG) with oral glucose tolerance testing for diagnosis of pre-diabetes.



Supplementary Figure 7. Schematic of conceptual framework of clinical application of A1c+ and A1c/FPG+ models.

References

1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. May 1 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
2. Diabetes NIo, Digestive, Diseases K. Diabetes Statistics. https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics
3. Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. *Diabetes Care*. Jan 1 2024;47(1):26-43. doi:10.2337/dci23-0085
4. Hanas R, John G, International HBAcCC. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. *Diabetes Care*. Aug 2010;33(8):1903-4. doi:10.2337/dc10-0953
5. ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic Targets: Standards of Care in Diabetes-2023. *Diabetes Care*. Jan 1 2023;46(Suppl 1):S97-S110. doi:10.2337/dc23-S006
6. Klein KR, Lingvay I, Tuttle KR, Flythe JE. Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure. *Diabetes Care*. Feb 1 2025;48(2):164-176. doi:10.2337/dci24-0081
7. Malkani S, Mordes JP. Implications of Using Hemoglobin A1C for Diagnosing Diabetes Mellitus. *The American Journal of Medicine*. 2011;124(5):395-401. doi:10.1016/j.amjmed.2010.11.025
8. Control CfD, Prevention\. *Data & Research | Chronic Kidney Disease*. 2024.
9. Diabetes NIo, Digestive, Diseases K. Overweight & Obesity Statistics. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity

10. Acquavella J, Mehra R, Bron M, Suomi JM, Hess GP. Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013-2016 in insured patients actively seeking care. *J Clin Sleep Med*. Aug 15 2020;16(8):1255-1263. doi:10.5664/jcsm.8482
11. Sharif A, Chakkera H, de Vries APJ, et al. International consensus on post-transplantation diabetes mellitus. *Nephrol Dial Transplant*. Feb 28 2024;39(3):531-549. doi:10.1093/ndt/gfad258
12. Paul JC, Fitzpatrick JJ. Postpartum glucose screening among women with gestational diabetes. *Appl Nurs Res*. Dec 2020;56:151341. doi:10.1016/j.apnr.2020.151341
13. Brown SD, Hedderson MM, Zhu Y, et al. Uptake of guideline-recommended postpartum diabetes screening among diverse women with gestational diabetes: associations with patient factors in an integrated health system in USA. *BMJ Open Diabetes Res Care*. Jun 2022;10(3)doi:10.1136/bmjdrc-2021-002726
14. Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the Time Needed to Provide Adult Primary Care. *J Gen Intern Med*. Jan 2023;38(1):147-155. doi:10.1007/s11606-022-07707-x
15. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. *Diabetes Metab Res Rev*. May-Jun 2000;16(3):164-71. doi:10.1002/1520-7560(200005/06)16:3<164::aid-dmrr103>3.0.co;2-r
16. Bang H, Edwards AM, Bomback AS, et al. Development and validation of a patient self-assessment score for diabetes risk. *Ann Intern Med*. Dec 1 2009;151(11):775-83. doi:10.7326/0003-4819-151-11-200912010-00005
17. Chen T, Guestrin C. XGBoost. presented at: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; 2016;
18. Hu C, Li L, Huang W, et al. Interpretable Machine Learning for Early Prediction of Prognosis in Sepsis: A Discovery and Validation Study. *Infect Dis Ther*. Jun 2022;11(3):1117-1132. doi:10.1007/s40121-022-00628-6
19. Zhang Q, Xu L, He W, Lai X, Huang X. Survival prediction for heart failure complicated by sepsis: based on machine learning methods. *Front Med (Lausanne)*. 2024;11:1410702. doi:10.3389/fmed.2024.1410702
20. Zheng J, Li J, Zhang Z, et al. Clinical Data based XGBoost Algorithm for infection risk prediction of patients with decompensated cirrhosis: a 10-year (2012-2021) Multicenter Retrospective Case-control study. *BMC Gastroenterol*. Sep 13 2023;23(1):310. doi:10.1186/s12876-023-02949-3
21. De Silva K, Lim S, Mousa A, et al. Nutritional markers of undiagnosed type 2 diabetes in adults: Findings of a machine learning analysis with external validation and benchmarking. *PLoS One*. 2021;16(5):e0250832. doi:10.1371/journal.pone.0250832
22. Esser K, Duong M, Kain K, et al. Predicting Diabetes in Canadian Adults Using Machine Learning. *Annu Int Conf IEEE Eng Med Biol Soc*. Jul 2024;2024:1-4. doi:10.1109/EMBC53108.2024.10782432
23. Liu X, Zhang W, Zhang Q, et al. Development and validation of a machine learning-augmented algorithm for diabetes screening in community and primary care settings: A population-based study. *Front Endocrinol (Lausanne)*. 2022;13:1043919. doi:10.3389/fendo.2022.1043919
24. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. *BMJ*. Apr 16 2024;385:e078378. doi:10.1136/bmj-2023-078378
25. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology*. Dec 1 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520
26. Group DS, Group obotEDE. Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria. *Archives of Internal Medicine*. 2001;161(3):397-405. doi:10.1001/archinte.161.3.397
27. Hutchison AL, Cifu AS, Pillai AA. Discarding Dichotomization: retrieving Data in the service of Patient Care. *Clinical Liver Disease*. 2022;19(1):12.

Section/Topic	Item	Development / evaluation[1]	Checklist item	Reported on page
TITLE				
Title	1	D;E	Identify the study as developing or evaluating the performance of a multivariable prediction model, the target population, and the outcome to be predicted	1,3,4
ABSTRACT				
Abstract	2	D;E	See TRIPOD+AI for Abstracts checklist	1
INTRODUCTION				
Background	3a	D;E	Explain the healthcare context (including whether diagnostic or prognostic) and rationale for developing or evaluating the prediction model, including references to existing models	3
	3b	D;E	Describe the target population and the intended purpose of the prediction model in the context of the care pathway, including its intended users (e.g., healthcare professionals, patients, public)	3, 7-9
	3c	D;E	Describe any known health inequalities between sociodemographic groups	3
Objectives	4	D;E	Specify the study objectives, including whether the study describes the development or validation of a prediction model (or both)	1, 3
METHODS				
Data	5a	D;E	Describe the sources of data separately for the development and evaluation datasets (e.g., randomised trial, cohort, routine care or registry data), the rationale for using these data, and representativeness of the data	3,4
	5b	D;E	Specify the dates of the collected participant data, including start and end of participant accrual; and, if applicable, end of follow-up	1, 4
Participants	6a	D;E	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including the number and location of centres	1, 3
	6b	D;E	Describe the eligibility criteria for study participants	3
	6c	D;E	Give details of any treatments received, and how they were handled during model development or evaluation, if relevant	NA
Data preparation	7	D;E	Describe any data pre-processing and quality checking, including whether this was similar across relevant sociodemographic groups	4
Outcome	8a	D;E	Clearly define the outcome that is being predicted and the time horizon, including how and when assessed, the rationale for choosing this outcome, and whether the method of outcome assessment is consistent across sociodemographic groups	1, 4
	8b	D;E	If outcome assessment requires subjective interpretation, describe the qualifications and demographic characteristics of the outcome assessors	NA
	8c	D;E	Report any actions to blind assessment of the outcome to be predicted	4
Predictors	9a	D	Describe the choice of initial predictors (e.g., literature, previous models, all available predictors) and any pre-selection of predictors before model building	1, 3, 4
	9b	D;E	Clearly define all predictors, including how and when they were measured (and any actions to blind assessment of predictors for the outcome and other predictors)	4
	9c	D;E	If predictor measurement requires subjective interpretation, describe the qualifications and demographic characteristics of the predictor assessors	NA
Sample size	10	D;E	Explain how the study size was arrived at (separately for development and evaluation), and justify that the study size was sufficient to answer the research question. Include details of any sample size calculation	4, 8, 9
Missing data	11	D;E	Describe how missing data were handled. Provide reasons for omitting any data	4, 8, 9
Analytical methods	12a	D	Describe how the data were used (e.g., for development and evaluation of model performance) in the analysis, including whether the data were partitioned, considering any sample size requirements	4
	12b	D	Depending on the type of model, describe how predictors were handled in the analyses (functional form, rescaling, transformation, or any standardisation).	4
	12c	D	Specify the type of model, rationale[2], all model-building steps, including any hyperparameter tuning, and method for internal validation	4
	12d	D;E	Describe if and how any heterogeneity in estimates of model parameter values and model performance was handled and quantified across clusters (e.g., hospitals, countries). See TRIPOD-Cluster for additional considerations[3]	NA
	12e	D;E	Specify all measures and plots used (and their rationale) to evaluate model performance (e.g., discrimination, calibration, clinical utility) and, if relevant, to compare multiple models	5-8
	12f	E	Describe any model updating (e.g., recalibration) arising from the model evaluation, either overall or for particular sociodemographic groups or settings	NA
	12g	E	For model evaluation, describe how the model predictions were calculated (e.g., formula, code, object, application programming interface)	4
Class imbalance	13	D;E	If class imbalance methods were used, state why and how this was done, and any subsequent methods to recalibrate the model or the model predictions	NA
Fairness	14	D;E	Describe any approaches that were used to address model fairness and their rationale	4
Model output	15	D	Specify the output of the prediction model (e.g., probabilities, classification). Provide details and rationale for any classification and how the thresholds were identified	1, 4

[1] D=items relevant only to the development of a prediction model; E=items relating solely to the evaluation of a prediction model; D;E=items applicable to both the development and evaluation of a prediction model

[2] Separately for all model building approaches.

[3] TRIPOD-Cluster is a checklist of reporting recommendations for studies developing or validating models that explicitly account for clustering or explore heterogeneity in model performance (eg, at different hospitals or centres). Debray et al, BMJ 2023; 380: e071018 [DOI: 10.1136/bmj-2022-071018]

Training versus evaluation	16	D;E	Identify any differences between the development and evaluation data in healthcare setting, eligibility criteria, outcome, and predictors	8-10
Ethical approval	17	D;E	Name the institutional research board or ethics committee that approved the study and describe the participant-informed consent or the ethics committee waiver of informed consent	NA
OPEN SCIENCE				
Funding	18a	D;E	Give the source of funding and the role of the funders for the present study	11
Conflicts of interest	18b	D;E	Declare any conflicts of interest and financial disclosures for all authors	11
Protocol	18c	D;E	Indicate where the study protocol can be accessed or state that a protocol was not prepared	4
Registration	18d	D;E	Provide registration information for the study, including register name and registration number, or state that the study was not registered	NA
Data sharing	18e	D;E	Provide details of the availability of the study data	9
Code sharing	18f	D;E	Provide details of the availability of the analytical code[4]	9
PATIENT & PUBLIC INVOLVEMENT				
Patient & Public Involvement	19	D;E	Provide details of any patient and public involvement during the design, conduct, reporting, interpretation, or dissemination of the study or state no involvement.	9
RESULTS				
Participants	20a	D;E	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	12
	20b	D;E	Report the characteristics overall and, where applicable, for each data source or setting, including the key dates, key predictors (including demographics), treatments received, sample size, number of outcome events, follow-up time, and amount of missing data. A table may be helpful. Report any differences across key demographic groups.	4, 10
	20c	E	For model evaluation, show a comparison with the development data of the distribution of important predictors (demographics, predictors, and outcome).	4
Model development	21	D;E	Specify the number of participants and outcome events in each analysis (e.g., for model development, hyperparameter tuning, model evaluation)	4-6
Model specification	22	D	Provide details of the full prediction model (e.g., formula, code, object, application programming interface) to allow predictions in new individuals and to enable third-party evaluation and implementation, including any restrictions to access or re-use (e.g., freely available, proprietary)[5]	4-6
Model performance	23a	D;E	Report model performance estimates with confidence intervals, including for any key subgroups (e.g., sociodemographic). Consider plots to aid presentation.	6-8
	23b	D;E	If examined, report results of any heterogeneity in model performance across clusters. See TRIPOD Cluster for additional details[3].	NA
Model updating	24	E	Report the results from any model updating, including the updated model and subsequent performance	NA
DISCUSSION				
Interpretation	25	D;E	Give an overall interpretation of the main results, including issues of fairness in the context of the objectives and previous studies	7,8
Limitations	26	D;E	Discuss any limitations of the study (such as a non-representative sample, sample size, overfitting, missing data) and their effects on any biases, statistical uncertainty, and generalizability	7,8
Usability of the model in the context of current care	27a	D	Describe how poor quality or unavailable input data (e.g., predictor values) should be assessed and handled when implementing the prediction model	7,8
	27b	D	Specify whether users will be required to interact in the handling of the input data or use of the model, and what level of expertise is required of users	7-9
	27c	D;E	Discuss any next steps for future research, with a specific view to applicability and generalizability of the model	7,8

From: Collins GS, Moons KGM, Dhiman P, et al. *BMJ* 2024;385:e078378. doi:10.1136/bmj-2023-078378

[4] This relates to the analysis code, for example, any data cleaning, feature engineering, model building, evaluation.
[5] This relates to the code to implement the model to get estimates of risk for a new individual.